Woodline Partners’s Monte Rosa Therapeutics GLUE Stock Holding History

Woodline Partners’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.23M	Buy	+74,496	New	+$1.42M	﹤0.01%	858
2023 Q1	–	Sell	-511,351	Closed	-$3.89M	–	697
2022 Q4	$3.89M	Buy	511,351 +8,940	+2%	+$74.5K	0.05%	354
2022 Q3	$4.11M	Buy	502,411 +126,403	+34%	+$1.16M	0.06%	336
2022 Q2	$3.64M	Buy	376,008 +327,908	+682%	+$3.29M	0.06%	305
2022 Q1	$674K	Buy	48,100 +75	+0.2%	+$1.04K	0.01%	503
2021 Q4	$981K	Sell	48,025 -86,008	-64%	-$1.8M	0.01%	505
2021 Q3	$2.99M	Sell	134,033 -74,035	-36%	-$2.12M	0.05%	340
2021 Q2	$4.72M	Buy	+208,068	New	+$4.24M	0.09%	229

Other funds holding GLUE

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Woodline Partners's GLUE Position: Q1 2026 in Review

Woodline Partners opened a new position in Monte Rosa Therapeutics (GLUE) in Q1 2026: 74,496 shares worth $1.23M. The stake represents ﹤0.01% of the portfolio and ranks #858 among its holdings. This is a return to the name: Woodline Partners previously reported a position in GLUE as recently as Q4 2022.

Woodline Partners first reported a position in GLUE in Q2 2021 and has held it in 8 quarters since. The position peaked at $4.72M in Q2 2021. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

Woodline Partners held 74,496 shares of Monte Rosa Therapeutics worth $1.23M as of Q1 2026.
Monte Rosa Therapeutics was a new Woodline Partners position in Q1 2026.
Monte Rosa Therapeutics made up ﹤0.01% of Woodline Partners's portfolio in Q1 2026, its #858 holding.
Woodline Partners first reported a position in Monte Rosa Therapeutics in Q2 2021 and has held it in 8 quarters since.
Woodline Partners's Monte Rosa Therapeutics position peaked at $4.72M in Q2 2021.
190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.